Status:
ACTIVE_NOT_RECRUITING
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS
Lead Sponsor:
University of Virginia
Conditions:
Leukemia, Acute
AML, Adult
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to estimate the potential benefit of early and continued palliative care (PC) consultation on end of life issues.
Detailed Description
Participants in this study will be randomized to either an intervention group or a standard of care group. Participants in the intervention group will participate in regular visits with a palliative (...
Eligibility Criteria
Inclusion
- Ability to provide informed consent
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Any of the following:
- Patients with a new diagnosis of AML, ALL, high risk myelodysplastic syndrome (MDS), or high risk chronic myelomonocytic leukemia (CMML) who are age 65 and older.
- OR
- Patients with relapsed AML, ALL, high risk MDS or high risk CMML, ages 18 and older.
- OR
- Patients with refractory AML, ALL, high risk MDS or high risk CMML, ages 18 and older.
- Refractory AML/ALL will be defined as persistent leukemia despite two or more cycles of induction chemotherapy.
- Refractory MDS will be defined according to the 2006 IWG response criteria Refractory CMML will be based on the assessment of the treating investigator.
Exclusion
- 1\. Participants must not have a diagnosis of Acute Promyelocytic Leukemia (APL)
Key Trial Info
Start Date :
August 19 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT04482894
Start Date
August 19 2020
End Date
April 1 2026
Last Update
May 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Virginia
Charlottesville, Virginia, United States, 22903